Article: Predicting response to peginterferon α-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B

File Download Links for fulltext
(May Require Subscription)
Supplementary
  • Basic View
  • Metadata View
  • XML View
TitlePredicting response to peginterferon α-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B
AuthorsBonino, F9 12
Marcellin, P16
Lau, GKK4
Hadziyannis, S15
Jin, R5
Piratvisuth, T1
Germanidis, G3
Yurdaydin, C6
Diago, M7
Gurel, S14
Lai, MY10
Brunetto, MR11
Farci, P13
Popescu, M2
McCloud, P8
Issue Date2007
PublisherB M J Publishing Group. The Journal's web site is located at http://gut.bmjjournals.com/
CitationGut, 2007, v. 56 n. 5, p. 699-705 [How to Cite?]
DOI: http://dx.doi.org/10.1136/gut.2005.089722
AbstractOBJECTIVE: In a trial of patients with hepatitis B e antigen (HBeAg)-negative chronic hepatitis B, 24 week post-treatment biochemical and virological response rates with peginterferon alpha-2a with or without lamivudine were significantly higher than with lamivudine alone. The effect of pre-treatment factors on post-treatment responses was investigated. METHODS: Multivariate analyses were performed using available data from 518 patients treated with peginterferon alpha-2a with or without lamivudine, or with lamivudine alone. A post-treatment response was defined as alanine aminotransferase (ALT) normalisation and hepatitis B virus (HBV) DNA level of <20,000 copies/ml. RESULTS: In logistic regression analyses across all treatment arms, peginterferon alpha-2a (with or without lamivudine) therapy, younger age, female gender, high baseline ALT, low baseline HBV DNA and HBV genotype were identified as significant predictors of combined response at 24 weeks post-treatment. In the peginterferon alpha-2a and lamivudine monotherapy arms, patients with genotypes B or C had a higher chance of response than genotype D infected patients (p<0.001), the latter responding better to the combination than to peginterferon alpha-2a monotherapy (p = 0.015). At 1 year post-treatment, response rates by intention-to-treat analysis were 19.2% for the peginterferon alpha-2a, 19.0% for the combination, and 10.0% for the lamivudine groups, with genotypes B or C associated with a sustained combined response to peginterferon alpha-2a with or without lamivudine therapy. CONCLUSIONS: Baseline ALT and HBV DNA levels, patient age, gender, and infecting HBV genotype significantly influenced combined response at 24 weeks post-treatment, in patients treated with peginterferon alpha-2a and/or lamivudine. At 1 year post-treatment HBV genotype was significantly predictive of efficacy for patients treated with peginterferon alpha-2a with or without lamivudine.
ISSN0017-5749
2011 Impact Factor: 10.111
2011 SCImago Journal Rankings: 0.883
DOIhttp://dx.doi.org/10.1136/gut.2005.089722
ISI Accession Number IDWOS:000245780200020
PubMed Central IDPMC1942152
DC Field
Value
dc.contributor.authorBonino, F
dc.contributor.authorMarcellin, P
dc.contributor.authorLau, GKK
dc.contributor.authorHadziyannis, S
dc.contributor.authorJin, R
dc.contributor.authorPiratvisuth, T
dc.contributor.authorGermanidis, G
dc.contributor.authorYurdaydin, C
dc.contributor.authorDiago, M
dc.contributor.authorGurel, S
dc.contributor.authorLai, MY
dc.contributor.authorBrunetto, MR
dc.contributor.authorFarci, P
dc.contributor.authorPopescu, M
dc.contributor.authorMcCloud, P
dc.date.accessioned2010-04-12T01:39:05Z
dc.date.available2010-04-12T01:39:05Z
dc.date.issued2007
dc.description.abstractOBJECTIVE: In a trial of patients with hepatitis B e antigen (HBeAg)-negative chronic hepatitis B, 24 week post-treatment biochemical and virological response rates with peginterferon alpha-2a with or without lamivudine were significantly higher than with lamivudine alone. The effect of pre-treatment factors on post-treatment responses was investigated. METHODS: Multivariate analyses were performed using available data from 518 patients treated with peginterferon alpha-2a with or without lamivudine, or with lamivudine alone. A post-treatment response was defined as alanine aminotransferase (ALT) normalisation and hepatitis B virus (HBV) DNA level of <20,000 copies/ml. RESULTS: In logistic regression analyses across all treatment arms, peginterferon alpha-2a (with or without lamivudine) therapy, younger age, female gender, high baseline ALT, low baseline HBV DNA and HBV genotype were identified as significant predictors of combined response at 24 weeks post-treatment. In the peginterferon alpha-2a and lamivudine monotherapy arms, patients with genotypes B or C had a higher chance of response than genotype D infected patients (p<0.001), the latter responding better to the combination than to peginterferon alpha-2a monotherapy (p = 0.015). At 1 year post-treatment, response rates by intention-to-treat analysis were 19.2% for the peginterferon alpha-2a, 19.0% for the combination, and 10.0% for the lamivudine groups, with genotypes B or C associated with a sustained combined response to peginterferon alpha-2a with or without lamivudine therapy. CONCLUSIONS: Baseline ALT and HBV DNA levels, patient age, gender, and infecting HBV genotype significantly influenced combined response at 24 weeks post-treatment, in patients treated with peginterferon alpha-2a and/or lamivudine. At 1 year post-treatment HBV genotype was significantly predictive of efficacy for patients treated with peginterferon alpha-2a with or without lamivudine.
dc.description.naturepublished_or_final_version
dc.identifier.citationGut, 2007, v. 56 n. 5, p. 699-705 [How to Cite?]
DOI: http://dx.doi.org/10.1136/gut.2005.089722
dc.identifier.doihttp://dx.doi.org/10.1136/gut.2005.089722
dc.identifier.isiWOS:000245780200020
dc.identifier.issn0017-5749
2011 Impact Factor: 10.111
2011 SCImago Journal Rankings: 0.883
dc.identifier.openurl
dc.identifier.pmcidPMC1942152
dc.identifier.pmid17127704
dc.identifier.scopuseid_2-s2.0-34247538953
dc.identifier.urihttp://hdl.handle.net/10722/57523
dc.languageeng
dc.publisherB M J Publishing Group. The Journal's web site is located at http://gut.bmjjournals.com/
dc.rightsGut. Copyright © B M J Publishing Group.
dc.rightsCreative Commons: Attribution 3.0 Hong Kong License
dc.subject.meshAntiviral Agents - therapeutic use
dc.subject.meshHepatitis B, Chronic - drug therapy - virology
dc.subject.meshInterferon Alfa-2a - therapeutic use
dc.subject.meshPolyethylene Glycols - therapeutic use
dc.subject.meshLamivudine - therapeutic use
dc.titlePredicting response to peginterferon α-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B
dc.typeArticle
Author Affiliations
  1. Prince of Songkla University
  2. F. Hoffmann-La Roche AG
  3. Papageorgiou General Hospital
  4. The University of Hong Kong
  5. Beijing Youan Hospital
  6. Ankara Üniversitesi
  7. Hospital General Universitario de Valencia
  8. Roche
  9. Università di Pisa
  10. National Taiwan University Hospital
  11. Azienda Ospedaliera-Universitaria Pisana
  12. IRCCS Foundation Rome
  13. Università degli Studi di Cagliari
  14. Uludağ Üniversitesi
  15. Henry Dunant Hospital
  16. Hopital Beaujon